Spring House, PA, United States of America

Stephanie A Barros

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.5

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):

Title: Stephanie Barros: Innovator in Inflammatory Disease Treatment

Introduction

Stephanie Barros is a prominent inventor based in Horsham, PA (US). She has made significant contributions to the field of biomedical research, particularly in the development of treatments for inflammatory diseases. Her innovative work has led to the creation of a patent that addresses critical health issues.

Latest Patents

Stephanie Barros holds a patent for "Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases." This invention provides novel peptide inhibitors that target the interleukin-23 receptor. The related compositions and methods are designed to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases. She has 1 patent to her name, showcasing her dedication to advancing medical science.

Career Highlights

Throughout her career, Stephanie has worked with notable companies in the biotechnology sector. She has been associated with Janssen Biotech, Inc. and Protagonist Therapeutics, Inc., where she has contributed her expertise in developing innovative therapies. Her work has been instrumental in pushing the boundaries of what is possible in treating complex inflammatory conditions.

Collaborations

Stephanie has collaborated with esteemed colleagues, including Chengzao Sun and Brian Troy Frederick. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Stephanie Barros is a trailblazer in the field of inflammatory disease treatment, with her innovative patent and collaborative efforts paving the way for future advancements. Her contributions are vital in the ongoing battle against inflammatory diseases, and her work continues to inspire others in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…